DEA cough/cold ingredient seizure upheld
This article was originally published in The Tan Sheet
Executive Summary
The U.S. Court of Appeals for the District of Columbia Circuit affirms the dismissal of a complaint filed by Malladi Drugs & Pharmaceuticals against the Drug Enforcement Administration seeking the return of $1.42 million worth of seized ephedrine and pseudoephedrine. The court's Jan. 23 ruling says India-based Malladi, which manufactures OTC and Rx pharmaceutical ingredients in the U.S. through subsidiary Novus Fine Chemicals, "failed to exhaust its administrative remedies" with DEA immediately following the seizure, such as filing a claim for the property. DEA agents seized the chemicals from Malladi's New Jersey facility in 2005 after discovering the company's file room was not sufficiently organized to reconcile documentation and inventory
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.